Is mycophenolate mofetil really necessary in renal transplantation? A review of the MYSS follow-up study

Nature Clinical Practice Nephrology

Volumn 3, Issue 11, 2007, Pages 602-603

  Brennan, Daniel C ^a,b   Koch, Matthew J ^a  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azathioprine; Chronic allograft dysfunction; Mycophenolate mofetil; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

EID: 35548953660     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0597     Document Type: Note

References (4)

1. Halloran P et al. (1997) Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63: 39-47
2. Ojo AO et al. (2000) Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69: 2405-2409
3. Meier-Kriesche HU et al. (2003) Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75: 1341-1346
4. Remuzzi G et al. (2004) Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 364: 503-512